Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alevatrix
- Development stage
- Unknown
- Lead developer
- Rebel Medicine
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Administration
- Injectable, Local Infiltration
01
Overview
Alevatrix is a novel, long-acting injectable formulation of bupivacaine, a well-characterized local anesthetic. It utilizes Rebel Medicine's proprietary extended-release matrix technology to provide sustained drug release at the site of administration for up to 72–96 hours following surgery. The primary goal of Alevatrix is to reduce or eliminate the need for opioids in post-operative pain management by delivering prolonged non-opioid analgesia with a favorable safety profile. Preclinical studies have demonstrated robust multi-day pain relief and good tolerability, and clinical trials are underway to assess its efficacy and safety in surgical patients[1][2][3][4][7][9].
- Brand names
- Alevatrix
- Other names
- Alevatrix
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on Alevatrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alevatrix.